Lloyds Banking Share Discussion Threads

[k38] 21/1/2021 23:13

Biden seeking five-year extension of nuclear arms treaty with Russia. W.H press secretary said "will work with Russia but we will blame them with... everything more less.and among other as she said, the interference with the 2020 elections. Lol...........

[k38] 21/1/2021 23:06

The remainers wanted a deal even a half deal... and this is what you get from the haters in Brussels. This is why a no deal was the best deal.Stop blaming Boris. It's a remainers fault!

[maxk] 21/1/2021 23:01

Doris and co dont do detail.

[hoper1] 21/1/2021 21:20

Nice find Opto. That helps with the decision making, although nothing is certain in these uncertain times. Stay safe.

[joestalin] 21/1/2021 20:53

What shall I tell him?

[maxk] 21/1/2021 20:52

Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
21/01/2021 6:51pm
Dow Jones News

Eli Lilly (NYSE:LLY)
Intraday Stock Chart

Thursday 21 January 2021
By Peter Loftus


Eli Lilly & Co. said its antibody-based drug prevented Covid-19 among many residents and staff of nursing homes and assisted-living facilities, results that point to the drug complementing vaccines while inoculations increase.

The drug, called bamlanivimab, reduced the risk of both staff and residents getting sick with Covid-19 by about 57% compared with a placebo eight weeks after receiving doses, Lilly said Thursday. The effect was more pronounced among residents, the company said, an 80% reduction in risk of Covid-19.

The findings signal the potential for a new preventive weapon that could augment the fledgling Covid-19 vaccination effort to stem the pandemic.

Lilly said it would ask U.S. health regulators to widen the drug's authorized use to include protecting people in long-term-care facilities where someone has recently been diagnosed with Covid-19.

The partial results were from a last-stage, or Phase 3, study conducted in partnership with the National Institutes of Health. Lilly disclosed the data in a news release and said it plans to publish full results in a peer-reviewed medical journal.

In November, the U.S. Food and Drug Administration authorized bamlanivimab to treat people already sick with mild to moderate Covid-19, based on a prior study showing it helped improve symptoms and kept patients out of the hospital.

Lilly Chief Scientific Officer Daniel Skovronsky said it would be useful to give bamlanivimab as a preventive measure because not all long-term-care residents and staff have received the new Covid-19 vaccines.

"We want to try to get this to people in nursing homes," he said in an interview. "It's not an alternative for a vaccine. It's for people who haven't been vaccinated, and there's an outbreak in their facility -- this could be a last resort."

Nursing homes and other senior-care facilities have been hit hard by the coronavirus, accounting for a large percentage of deaths during the pandemic. A Wall Street Journal review found the facilities were tied to a third of Covid-19 deaths world-wide.

Residents are at risk of exposure because of the congregate setting, and of severe disease because most are elderly or have underlying health conditions.

So far, at least 1.9 million Covid-19 vaccine doses have been administered in long-term-care facilities, according to the U.S. Centers for Disease Control and Prevention. It estimates there are about 3 million residents of long-term-care facilities in the U.S., each needing two doses of the new vaccines.

Yet hesitancy among facility staff to receive the shots has slowed the rollout of the vaccines in the facilities, which are being administered by pharmacy chains CVS Corp. and Walgreens Boots Alliance Inc.

Lilly started the 5,000-subject study in August in U.S. nursing homes that had a recently diagnosed case of Covid-19, putting residents and staff at high risk of exposure. The study is ongoing and is also testing combining bamlanivimab with another antibody.

Once a case was diagnosed, other residents and staff were tested for Covid-19 and offered an intravenous infusion of bamlanivimab. For people who tested positive, the study also tracked whether bamlanivimab was effective as a treatment.

The prevention data that Lilly released was from 965 people -- 299 residents and 666 staff -- who had tested negative for the virus at the start of the study.

Among these residents, four people subsequently contracted the disease and died from it, and all had received a placebo. No residents who tested negative and received the Lilly drug died from the disease, Lilly said.

Lilly said side effects of the drug in the new study were consistent with what was seen in prior studies, with small percentages experiencing nausea, dizziness and headache.

The federal government has agreed to purchase about 950,000 doses of Lilly's antibody for about $1.2 billion, and to make the doses free to patients.

The FDA authorized a similar antibody-based treatment from Regeneron Pharmaceuticals Inc., one that had been given to then-President Donald Trump for treatment of Covid-19 in October.

The drugs belong to a class of medicines known as monoclonal antibodies that are designed in labs to mimic the naturally occurring antibodies that the immune system produces to fight off viruses and other foreign invaders.

Lilly developed its drug in collaboration with AbCellera Biologics Inc., of Vancouver, British Columbia, which isolated antibodies from a blood sample taken from one of the first Americans to recover from Covid-19.

Since their authorizations, however, the antibody products haven't been used to treat sick patients as widely as the companies or federal health officials had hoped. Some infectious-disease specialists have cited limited evidence of their effectiveness, while primary-care doctors sometimes aren't aware of the option.

About 454,000 doses of Lilly's antibody have been distributed in the U.S., according to the U.S. Department of Health and Human Services.

Dr. Skovronsky said he hopes the new treatment results from the nursing-home study will give doctors more confidence to use the drug in patients.

Dr. Rajesh Gandhi, an infectious-diseases physician at Massachusetts General Hospital and Harvard Medical School, said the results look promising and he looks forward to seeing more details and published data. "We desperately need effective measures to prevent and treat Covid-19 outbreaks in congregate settings, even as we accelerate vaccine rollout," he said.

Dr. Gandhi is one of the co-authors of guidelines issued by the Infectious Disease Society of America which recommend against the routine use of bamlanivimab to treat nonhospitalized patients with Covid-19, citing thin evidence of its benefit. The IDSA guidelines say the drug is a reasonable treatment option for infected patients who are high risk of worsening to severe disease. The guidelines don't currently address use of the drug as a preventive measure.

Lilly also is developing additional antibody treatments for Covid-19. The company believes bamlanivimab will still be effective against the coronavirus variant that has spread in the U.K., but has less confidence it can work against a different variant identified in South Africa, Dr. Skovronsky said.

Yet he added that Lilly should be able to develop an antibody that would work against the South African variant.

Write to Peter Loftus at [e-mail]

[joestalin] 21/1/2021 20:12

Read the Bible - Exodus - it's all foretold there?

No - it was Act 1, Scene 1 of Macbeth.

[asa8] 21/1/2021 20:00

God help America will all end in tears as for all those celebs harping on about
Biden anyone would think it was the second
Coming

[cobourg1] 21/1/2021 19:34

Ultimately we're only delaying the inevitable at the moment....

.................................................................................

And I'll tell you another thing for nothing. All our first born children are going to die and there will be a plague of frogs and flies and all our rivers will turn putrid. Read the Bible - Exodus - it's all foretold there.

I blame Brexit myself, the weather has never been the same since we left. Well it's either that or Boris Johnson's untidy hair, although I do quite fancy Carrie.

[freddie01] 21/1/2021 18:58

Rolls-Royce has successfully completed the first engine run on its new £90 million testbed in Derby. Testbed 80 will be the largest facility of its type in the world when it is officially opened in the coming months #UKmfgFlag of United Kingdom

[k38] 21/1/2021 17:55

Surprise, Surprise – Literally one hour after Biden was sworn in, the World Health Organization admitted that PCR testing produces  high amplification rates and results and a huge number of false positives.The WHO released a report today saying that their COVID testing overstates the number of false positives:literally one hour after Biden takes the oath, the WHO admits that PCR testing at high amplification rates alters the predictive value of the tests and results in a huge number of false positives pic.twitter.com/iDtXmappRw- Andy Swan (@AndySwan) January 20, 2021

[k38] 21/1/2021 17:50

Good reading.https://thetruedefender.com/ideological-alignment-pushing-america-toward-totalitarianism-experts-warn/

[ladeside] 21/1/2021 17:36

The problems haven't started yet, they'll begin once furlough ends and once companies are hit with the double whammy of covid and Brexit fall out.

Realistically we're looking at the second half of 2022 before the fallout and actual unemployment figures become apparent as we've not even had the 90 day notice periods issued yet, once that starts filtering through there will be a huge hit to the economy, defaults, repossessions and companies falling like dominoes.

Ultimately we're only delaying the inevitable at the moment....

[chavitravi2] 21/1/2021 14:19

Another piece of good news for banks and share holders.
8 in 10 of customers on the mortgage payment holiday are now paying in full.
In June there was 1.8 million on the scheme, at the end of December there was 130,000. That should help the balance sheet.

[optomistic] 21/1/2021 14:00

A little something to read on a dull day....

The Lloyds share price (LON:LLOY) staged a white-knuckle ride of a rally in late 2020, before making a retracement into the close of the year.

Despite the sharp pull-back, Lloyds has more to offer investors in 2021 with shares valued attractively and the prospect of a UK economic recovery likely to boost sentiment around Lloyds shares.

As we have previously noted when analysing Lloyds, valuing Lloyds by their profitability during the pandemic can be a perilous pursuit as UK banks’ profits have been ravaged by the Black Swan event of COVID-19, making the past 12 months earnings a poor barometer of earnings in the future.

In addition, profits over the next couple of quarters will be unpredictable and largely correlated to short-term government decisions on economic lockdown restrictions.

We would look to the book value or net asset value of Lloyds as the foremost valuation methodology.

Lloyds shares

During the pandemic, investors have effectively marked down their perceptions of what Lloyds assets are worth due to the risks of default caused by a severe economic downturn.

The Lloyds share price fell as low as 24p in 2020, before recovering.


Now that the worst of the economic uncertainty is behind us with the roll out of vaccines, the market is likely to reduce their risk rating attached to Lloyds shares as the chances of significant rates of default diminish.

The end of the furlough scheme and changes to taxes in the UK still pose potential threats to the underlying health of the UK economy, and Lloyds profitability, but these are favourable when compared to a protracted pandemic and lockdown.

With Lloyds shares trading at roughly 50% of the Book Value of the company, there is plenty of space for shares to move to the upside and back in line with historical averages.

Lloyds Dividend

There is also the prospect of the bank resuming the payments of dividends in the near term. Lloyds, along with all other UK banks, ceased the payments of dividends after a warning from the Bank of England they must conserve cash to see them through the coronavirus pandemic.

With the pandemic seemingly moving towards its final stages after the approval of the third vaccine in the UK, The Bank of England have lifted guidance against paying dividends meaning Lloyds are now free start paying dividends again.

Investors should expect dividend guidance in Lloyds next update, but also understand the resumption of dividends will likely be gradual over the coming reporting periods.

Nonetheless, the additional buying pressure from income investors returning to the stock will provide support for the share price going forward.

The combination of anticipation surrounding the Lloyds dividend and the low Price-to-Book valuation means the 2021 trading year is likely to be a positive one for the Lloyds share price, discounting any unexpected bad news concerning coronavirus.

[maxk] 21/1/2021 13:15

Just wait till Speepy Joe supporters twig that they have been sold the Brooklyn Bridge.

[utrickytrees] 21/1/2021 13:07

Lol, minimum wage $7.25 that's about £2.50